Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.86 |
| ▸ | PTPRC | P08575 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL8934985 | 1.00 | SLC7A5 (0.86) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL192543 | 1.00 | SLC7A5 (0.86) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL15689273 | 1.00 | SLC7A5 (0.86) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL29230366 | 1.00 | SLC7A5 (0.86) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL28873419 | 0.98 | SLC7A5 (0.83) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL28831604 | 0.98 | SLC7A5 (0.83) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL20558574 | 0.98 | SLC7A5 (0.83) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL5499765 | 0.97 | SLC7A5 (0.80) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL9715667 | 0.93 | SLC7A5 (0.80) | SLC7A5PTPRCPTGS1ALPIPKM | |
| Tyrosine SCHEMBL11676395 | 0.93 | SLC7A5 (1.00) | SLC7A5PTPRCPTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119310285-A | Detection card and kit for quantitative joint detection of tyrosine phosphatase antibody and zinc transport protein 8 antibody | 广州达安基因股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240293334-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2024-09-05 | — | — | US | claimed |
| US-11883541-B2 | Nonviral gene transfer to the suprachoroidal space | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-01-30 | — | — | US | claimed |
| US-20220257625-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | BIODERM, INC. | 2022-08-18 | — | — | US | claimed |
| WO-2021011664-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | BIODERM, INC. (US) | 2021-01-21 | — | — | WO | claimed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | claimed |
| CN-111378042-A | Cerenkov fluorescence imaging probe and preparation method and application thereof | 哈尔滨医科大学 | 2020-07-07 | — | — | CN | claimed |
| WO-2019070727-A2 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-04-11 | — | — | WO | claimed |
| CN-109414482-A | Peptides and methods for treating neurodegenerative diseases | 俄亥俄州创新基金会 | 2019-03-01 | — | — | CN | claimed |
| CN-108165606-A | Using carbon dots as the Assay of acid phosphatase content method of photolytic activity analogue enztme | 江南大学 | 2018-06-15 | — | — | CN | claimed |
| WO-1998027065-A1 | MODULATORS OF PROTEINS WITH PHOSPHOTYROSINE RECOGNITION UNITS | ONTOGEN CORPORATION (US) | 1998-06-25 | — | — | WO | claimed |
| US-5753687-A | ACRYLATED ARYLIMIDAZOLE DERIVATIVES | ONTOGEN CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | claimed |
| WO-1997039748-A1 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| CN-1137826-A | Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders | NEW YORK UNIV MEDICAL CENTER (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | claimed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | claimed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883541-B2 | Nonviral gene transfer to the suprachoroidal space | MYOC, MTREX, SLC26A4 | OPRM1 4464/4885KCNH2 4056/4885SLC7A5 693/4885 |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | OPRM1 4464/4885KCNH2 4056/4885SLC7A5 693/4885 |
| US-20240293334-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | OPRM1 4464/4885KCNH2 4056/4885SLC7A5 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.